GLP1R and coronary artery disorder: This suggests that: (1) in the chronic inflammatory process of CHD, changes in GLP-1R expression level are more sensitive than relative macrophage content; (2) the reduction of GLP-1R on beneficial anti-inflammatory type (M2) macrophage in CHD patients may explain that GLP-1R receptor agonists are independent of glycemic control effects, thus benefits for CHD.